Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High – Here’s Why

Takeda Pharmaceutical Co. (NYSE:TAK)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $15.74 and last traded at $15.7350, with a volume of 158136 shares. The stock had previously closed at $15.65.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

The firm has a market cap of $50.13 billion, a P/E ratio of 196.69 and a beta of 0.03. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37. The stock’s 50-day moving average is $14.28 and its 200 day moving average is $14.61.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.44. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.The firm had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. On average, research analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

A number of large investors have recently bought and sold shares of the business. Twin Peaks Wealth Advisors LLC bought a new position in Takeda Pharmaceutical in the second quarter valued at approximately $28,000. Evelyn Partners Investment Management LLP raised its holdings in shares of Takeda Pharmaceutical by 163.4% during the second quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock worth $39,000 after acquiring an additional 1,560 shares during the period. True Wealth Design LLC lifted its position in Takeda Pharmaceutical by 1,262.3% in the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock valued at $40,000 after acquiring an additional 2,512 shares in the last quarter. NewSquare Capital LLC boosted its stake in Takeda Pharmaceutical by 182.4% in the 2nd quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock worth $53,000 after purchasing an additional 2,229 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after purchasing an additional 1,292 shares during the period. 9.17% of the stock is owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.